WASHINGTON, United States — The United States Supreme Court has allowed continued access to the abortion pill mifepristone via telemedicine and mail delivery, temporarily restoring a federal rule that had eased restrictions on its distribution while a legal challenge continues.
In an unsigned emergency order issued on Thursday, the court lifted a lower court ruling that had blocked a 2023 federal regulation introduced under the administration of former President Joe Biden.
The rule had eliminated the requirement for an in-person clinician visit before receiving the medication, making access easier across the country.
The decision came after drug manufacturers Danco Laboratories and GenBioPro appealed a ruling by the New Orleans-based 5th U.S. Circuit Court of Appeals, which on 1 May had reinstated earlier restrictions requiring in-person visits to obtain mifepristone.
The Supreme Court’s order preserves the current regulatory framework for now as litigation continues.
The case originates from a challenge filed by Louisiana, which argues that the relaxed federal rules conflict with state-level abortion restrictions enacted after the 2022 Supreme Court decision in Dobbs v. Jackson Women’s Health Organization, which overturned the constitutional right to abortion established under Roe v. Wade.
The court’s brief order provided no reasoning, a standard practice in emergency rulings. However, Justices Samuel Alito and Clarence Thomas dissented. Alito argued that mail distribution of abortion medication undermines state laws restricting abortion access, while Thomas cited the federal Comstock Act, suggesting it prohibits mailing abortion-related drugs.
The case has once again placed abortion access at the centre of the United States’ legal and political debate, particularly ahead of closely contested congressional elections. The Supreme Court’s 6–3 conservative majority continues to face pressure from competing political and legal interpretations of reproductive rights.
The Biden-era Food and Drug Administration rule at the heart of the dispute was based on evidence supporting the safety and effectiveness of mifepristone, which has been approved since 2000. Medical groups, including the American College of Obstetricians and Gynecologists, maintain that medication abortion is safe, with complications described as rare when used as directed.
Abortion rights advocates welcomed the decision, arguing it preserves access to essential healthcare while litigation continues. Planned Parenthood said the ruling offers relief to patients who rely on telemedicine for reproductive care, while advocacy groups warned that continued legal challenges could still disrupt access in the future.
The case is part of a broader wave of litigation across several Republican-led states seeking to further restrict or eliminate access to Mifepristone, setting up a continuing legal battle over the scope of federal authority versus state abortion laws in the post-Dobbs era.
As proceedings continue, the Supreme Court’s interim ruling maintains the status quo, leaving the future of telemedicine abortion access in the United States unresolved.
